Literature DB >> 27803307

Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour.

Cosimo Bruni1, Ana Lages2, Hitesh Patel3, Svetlana I Nihtyanova4, Bryan Green5, Mohammed AbuHilal6, Jennifer Harvey3, Voon H Ong4, Marco Matucci Cerinic1, Emma Derrett-Smith4,7, Christopher P Denton8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27803307     DOI： 10.1093/rheumatology/kew382

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

Review 1.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

2.  Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.

Authors:  Takeru Igusa; Laura K Hummers; Kala Visvanathan; Carrie Richardson; Fredrick M Wigley; Livia Casciola-Rosen; Antony Rosen; Ami A Shah
Journal:  Ann Rheum Dis       Date:  2018-04-20       Impact factor: 19.103

3.  Mechanistic and clinical insights at the scleroderma-cancer interface.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  J Scleroderma Relat Disord       Date:  2017-10-05

4.  Scleroderma Renal Crisis in a Systemic Sclerosis With Anti-PM/Scl Antibodies.

Authors:  Marine Jacquier; Christiane Mousson; Jean-Michel Rebibou; Daniela Lakomy; Stéphanie François; Laurent Martin; Mathilde Funes De La Vega; Mathieu Legendre
Journal:  Kidney Int Rep       Date:  2019-07-10

5.  Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM/Scl Antibody.

Authors:  Yongpeng Ge; Xiaoming Shu; Linrong He; Chunjia Li; Xin Lu; Guochun Wang
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.